Risk for second primary cancer higher in patients who smoked prior to first cancer
the ONA take:
A significant behavior that increases the risk of developing cancer is cigarette smoking. This fact has been proven in countless studies, and a recent pooled analysis of five prospective cohort studies indicates that the cancer risk goes beyond developing a first primary cancer.
The analysis shows that patients who smoked 20 or more cigarettes a day prior to a diagnosis of lung (stage I), bladder, kidney, or head and neck cancer were at increased risk of developing a second primary smoking-associated cancer compared with patients who had never smoked and had survived the same first cancers. The researchers note the second primary cancers are not metastases of the first cancer, but distinct new malignancies.
Smokers who smoked fewer than 20 cigarettes per day and former smokers who had quit before their first cancer diagnosis also were at higher risk of developing a second cancer. This is the first study to explore the risk of second primary cancers in current smokers.
Although further research is needed to assess the association between smoking after a first cancer and second cancer risk, these results further support encouraging smoking cessation to all patients who smoke.
A significant behavior that increases the risk of developing cancer is cigarette smoking.
Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.
An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|